The Present and Future of Prostatitis.
10.4111/kju.2008.49.6.475
- Author:
In Rae CHO
1
Author Information
1. Department of Urology, Inje University College of Medicine, Gimhae, Korea. ircho@paik.ac.kr
- Publication Type:Controlled Clinical Trial ; Review ; Clinical Trial
- Keywords:
Prostatitis;
Chronic pelvic pain syndrome;
Etiology;
Treatment;
Neurogenic inflammation
- MeSH:
Antidepressive Agents, Tricyclic;
Cholinergic Antagonists;
Follow-Up Studies;
Humans;
Neurogenic Inflammation;
Pelvic Pain;
Prostatitis
- From:Korean Journal of Urology
2008;49(6):475-489
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Prostatitis is a common disease that is confusing and frustrating for urologists. Chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) is the most common form of prostatitis. The etiology of CP/CPPS is unknown, but possibilities include infectious, autoimmune, neurological, endocrine and psychological causes. Clinical evaluation can aid in diagnosis and follow-up of the patient's response to therapy. Treatment for CP/CPPS is empiric and limited by a lack of randomized, placebo- controlled clinical trials. Antimicrobials are commonly used to treat patients with prostatitis. Other commonly used drugs include alpha-adrenoceptor antagonists, anti-inflammatory drugs, tricyclic antidepressants, and anticholinergic agents. Also, minimally invasive procedures are considered in patients with CP/CPPS and It is possible to treat intractable patients with invasive treatment. Although much progress has been made in therapy, there is no distinct treatment for patients with CP/CPPS. If the concept of neurogenic inflammation with pain is solved, it is possible to treat patients with CP/CPPS at future.
